Using Lipid Nanoparticles to Efficiently Deliver CRISPR/Cas9 for Genome Editing

S. C. Alexander et al.

Transthyretin amyloidosis (ATTR) is a progressive disease caused by accumulation of amyloid deposits of misfolded transthyretin (TTR) protein in multiple tissues including the heart, nerves and gastrointestinal tract. Reduction of TTR monomer via stabilization of circulating tetramer and silencing of TTR gene expression in hepatocytes of ATTR patients have emerged as successful therapeutic strategies for chronically-administered medicines. As such, specific disruption (or knockout) of the TTR gene in hepatocytes using the CRISPR/Cas9 gene editing system is a potentially attractive next- generation treatment for ATTR, which may durably reduce the expression of TTR without the need for chronic therapy.

… NTLA-2001 achieves significant knockdown of the TTR protein by editing the TTR gene across multiple species, including mouse and NHP

Demonstrated the potential of LNP-delivered in vivo CRISPR/Cas9 gene editing; suggests that future therapies based on this platform may enable next-generation, curative treatment paradigms for chronic genetic diseases such as ATTR

Latest articles

Craig Paardekooper An FOIA request by Judicial Watch led to the disclosure...
Dobrin Draganov et al. Ivermectin converts cold tumors hot and synergizes with...
Technocracy News Digital identity, digital twins, programmable central bank digital currency, a...
Aaron Kheriaty Unless we collectively decline to participate in this new social...
Robert O. Young Long-term exposure to wireless radiation is a proven health...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!